268 related articles for article (PubMed ID: 26901457)
1. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
[TBL] [Abstract][Full Text] [Related]
2. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
5. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
6. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
8. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for vascular complications of targeted cancer therapies.
Gopal S; Miller KB; Jaffe IZ
Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Toxic Effects of Targeted Cancer Therapies.
Moslehi JJ
N Engl J Med; 2016 Oct; 375(15):1457-1467. PubMed ID: 27732808
[No Abstract] [Full Text] [Related]
12. Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use.
Dasanu CA; Padmanabhan P; Clark BA; Do C
Expert Opin Drug Saf; 2012 May; 11(3):445-57. PubMed ID: 22469002
[TBL] [Abstract][Full Text] [Related]
13. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
15. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.
Bronte G; Bronte E; Novo G; Pernice G; Lo Vullo F; Musso E; Bronte F; Gulotta E; Rizzo S; Rolfo C; Silvestris N; Bazan V; Novo S; Russo A
Expert Opin Drug Saf; 2015 Feb; 14(2):253-67. PubMed ID: 25494575
[TBL] [Abstract][Full Text] [Related]
16. Cardio-oncological management of patients.
Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide and adverse events of vascular endothelial growth factor inhibitors.
Thachil J
Curr Med Res Opin; 2011 Aug; 27(8):1503-7. PubMed ID: 21651424
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
Yeh ETH; Ewer MS; Moslehi J; Dlugosz-Danecka M; Banchs J; Chang HM; Minotti G
Semin Oncol; 2019 Dec; 46(6):397-402. PubMed ID: 31753424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
